Organisation paid for research Program year 2025 Source: CMS Open Payments

Cleaver Dermatology

Neither a doctor nor a teaching hospital

Research payments

$204,101

77 payments

Through program year 2025, Cleaver Dermatology is reported as receiving $204,101 in research payments, across 77 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $81,344 25
2024 Research $97,191 12
2023 Research $5,909 11
2022 Research $5,387 13
2021 Research $12,098 11
2020 Research $2,173 5

Breakdown

Who paid Research payments · program years 2020–2025
  1. Janssen Research & Development, LLC $171,582 27 payments
  2. Regeneron Pharmaceuticals, Inc. $15,862 43 payments
  3. Pfizer Inc. $8,400 1 payment
  4. Acrotech Biopharma LLC $6,287 3 payments
  5. AbbVie, Inc. $1,970 3 payments
Studies the money was for Research payments · program years 2020–2025
  1. A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis $131,017 18 payments
  2. A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis $40,565 9 payments
  3. A Prospective Observational Study of Patients Receiving Dupixent for Atopic Dermatitis $9,991 28 payments
  4. Abrocitinib Expanded Access Protocol for the Treatment of Adolescents and Adults With Moderate to Severe Atopic Dermatitis $8,400 1 payment
  5. 246-13651-302 $6,287 3 payments
  6. A Prospective Observational Study of Adult Patients Receiving Dupixent for Atopic Dermatitis $5,871 15 payments
  7. A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab $1,713 1 payment
  8. A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis $157 1 payment
  9. A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) $101 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record